Lyell Immunopharma (LYEL) Operating Leases (2020 - 2026)

Lyell Immunopharma has reported Operating Leases for 7 years, with the latest figure at $39.5 million in Q1 2026.

• Quarterly Operating Leases fell 30.83% year-over-year to $39.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (down 30.83% YoY) and the FY2025 annual result came in at $41.9 million, down 17.79% from the prior year.
• Operating Leases eased to $39.5 million in Q1 2026 per LYEL's latest filing, from $41.9 million in the prior quarter.
• Over five years, Operating Leases peaked at $68.8 million in Q1 2022 and troughed at $39.5 million in Q1 2026.
• A 5-year average of $58.2 million and a median of $58.6 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2026: Operating Leases grew 9.84% in 2022, then sank 30.83% in 2026.
• Over 5 years, Operating Leases stood at $63.2 million in 2022, then declined by 9.93% to $56.9 million in 2023, then declined by 10.37% to $51.0 million in 2024, then declined by 17.79% to $41.9 million in 2025, then dropped by 5.81% to $39.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $39.5 million, $41.9 million, and $53.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.